Navigation Links
MGC Diagnostics Corporation Announces Worldwide Exclusive Distribution Partnership with Restech Respiratory Technology
Date:3/19/2013

SAINT PAUL, Minn., March 19, 2013 /PRNewswire/ -- MGC Diagnostics Corporation (NASDAQ: MGCD) (formerly Angeion Corporation), a global medical technology leader, today announced that it has entered into a worldwide distribution agreement with Restech Respiratory Technology (Restech Srl), a privately held company spun-off from the Politecnico di Milano, Italy, to  market and distribute the Resmon Pro, Forced Oscillation Technique (FOT) device. Manufactured by Restech Srl, the Resmon Pro aids in the diagnosis and treatment of respiratory disease. Typically, the diagnosis of common respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) involve complex measurements and maximum patient effort. Restech developed patented technology to determine the breath-by-breath presence and severity of expiratory flow limitation (EFL) during quiet breathing. Using the Resmon Pro, a physician can detect the presence, severity and reversibility of EFL, and evaluate the degree of airflow obstruction and shortness-of-breath experienced by the patient.

(Logo:  http://photos.prnewswire.com/prnh/20120821/LA60189LOGO)

Gregg O. Lehman , Ph.D., Chief Executive Officer and President of MGC Diagnostics, commented "Our agreement with Restech is an example of how MGC Diagnostics will execute strategic partnerships with emerging technology providers, both within the university sciences and entrepreneurial start-up sectors. Leveraging MGC Diagnostics global sales, marketing, and support network provides emerging technology companies best-in-class access to cardiorespiratory healthcare professionals and their patients throughout the world."

About Restech Respiratory TechnologyRestech SRL is a spinoff company of Politecnico di Milano derived from a Bioengineering Department research team of the Biomedical Technology Laboratory (TBMLab). Their primary focus is in the development of innovative products and services for the diagnosis, monitoring and management of patients affected by respiratory diseases.

About MGC DiagnosticsMGC Diagnostics Corporation, (formerly Angeion Corporation) through its subsidiary Medical Graphics Corporation, is a global medical technology company dedicated to cardiorespiratory health solutions. MGC Diagnostics develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.

Cautionary Statement Regarding Forward Looking StatementsFrom time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forward−looking statements concerning possible or anticipated future financial performance, business activities or plans that include the words "believes," "expects," "anticipates," "intends" or similar expressions. For these forward−looking statements, the Company claims the protection of the safe harbor for forward−looking statements contained in federal securities laws. These forward−looking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC, that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forward−looking statements. For a list of these factors¸ see the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements," in the Company's Form 10-K for the year ended October 31, 2012, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.Contact:

Gregg O. Lehman, Ph.D.Joe Dorame, Robert Blum, Joe DiazMGC Diagnostics Corporation

Lytham Partners, LLCChief Executive Officer

(602) 889-9700(651) 484-4874mgcd@lythampartners.com


'/>"/>
SOURCE MGC Diagnostics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Athena Diagnostics Announces New Genetic Testing Services for Rare Neurological Disorders
2. Quest Diagnostics Launches Dementia Diagnostic Panel, First in Industry for Treatable Forms of Cognitive Impairment Based on Medical Guidelines
3. Ariosa Diagnostics Introduces Y-Chromosome Analysis Test Option
4. PET/MR Scanner Holds Promise For Expanded Diagnostics
5. In Vitro Diagnostics Markets Grow at Double the Pace of Pharma Markets in Shift toward Globalization
6. MGC Diagnostics Corporation Reports 2013 First Fiscal Quarter Operating Results
7. MD Buylines User Satisfaction Report Awards MGC Diagnostics Pulmonary Function Products Top Rating for Fourth Consecutive Quarter
8. MGC Diagnostics Corporation Announces Partnership with Frontera Strategies, LP
9. MGC Diagnostics Corporation to Report First Quarter Fiscal 2013 Financial Results on Tuesday, March 5, 2013
10. Quest Diagnostics to Sell HemoCue Business to Radiometer Medical ApS
11. Quest Diagnostics to Provide Nationwide Access to Nateras New Non-Invasive Prenatal Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
Breaking Medicine News(10 mins):